A Quarterly Update Px Wire: on HIV Prevention Research Volume 3 | No. 1 January–March 2010 Despite disappointing results, there is still much to AVAC’s Take be learned from this trial. Spanning four years and four countries—South Africa, Tanzania, Uganda and Zambia— The last three months of 2009 took us to an unprecedented MDP 301 can serve as a model for future HIV prevention place in the field of HIV prevention research. For the first trials. In addition to critical scientific information, it will time in history, a clinical trial showed that the prevention provide important data from its extensive social science of HIV through vaccination is possible. Researchers also component and lessons from the comprehensive discovered the first new neutralizing antibodies in over a community engagement and preparation undertaken decade that may be helpful in the creation of new vaccine by the trial staff. candidates. At the same time, news from microbicide and MDP 301 also underscores the need to continue the PrEP trials provided reminders of the challenges and search for new laboratory assays and animal models for complexities of biomedical HIV prevention trials. assessing safety and finding correlates of protective efficacy In the broader world of HIV/AIDS, the US government in humans. In both animal studies and the laboratory, repealed the decades-long bans on federal funding for Continues on back syringe exchange and on entry to the US for people with HIV. Both of these moves represent important steps forward for evidence-based HIV prevention. Looking ahead in 2010, we anticipate a cascade of safety At a Glance and adherence data from oral PrEP trials; results from a phase IIb trial of tenofovir gel; the launch of new trials • In October, the US National Institute of Allergy and looking at intermittent PrEP and the “test-and-treat” Infectious Diseases (NIAID) held a workshop, Beyond strategy; and other events we can’t predict. We hope you’ll 2010: Gaps, Challenges, and Priorities for the Future of continue to join with AVAC as we navigate what promises Preclinical PrEP, to discuss opportunities, challenges to be an exciting year together. and priorities related to the development and discovery of new PrEP agents. The two-day meeting featured presentations from Data Dispatch drug development and animal research scientists geared toward defining the target product profile PRO 2000: The final word for new PrEP agents, identifying priority areas for Last December, the Microbicides Development Programme investigation in animal models, and establishing a (MDP) released results from the microbicide trial MDP 301. research agenda around correlates of protection. The trial showed that PRO 2000 (0.5%) gel is safe but not effective in reducing women’s risk of HIV infection during • In December, AVAC collaborated with amfAR in vaginal sex. Analysis of the trial data found no difference in convening a special scientific think tank on rates of HIV infection between the PRO 2000 and placebo intermittent PrEP research. This meeting considered arms—a 4.1 percent rate in the PRO 2000 arm compared both biomedical and social science elements of a to a 4.0 percent rate in the placebo arm. The unambiguous results from the trial give a definitive answer that PRO 2000 developing intermittent PrEP research agenda. is not a viable microbicide. 2010 Trial Milestones to Watch* 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Launch of HPTN 066, phase I trial to Launch of HPTN 065 TNT-Plus, a study Results from CAPRISA 004, phase IIb trial Results from IAVI’s phase I/II trials evaluate the pharmacokinetics of to evaluate the feasibility of an enhanced to evaluate the safety and effectiveness of to evaluate the safety, acceptability, intermittent oral TDF/FTC (US) “test-and-treat” approach for the 1% tenofovir gel to prevent HIV infection adherence and drug levels of oral TDF/FTC prevention of HIV transmission (US) in women (South Africa) taken once daily vs. intermittently by Results from CDC 4323, phase II trial (US) men and women (Kenya, Uganda) Launch of HPTN 067, phase I/II feasibility trial to evaluate the behavioral aspects of Completion of CDC 4940 (TDF2) (Botswana) fixed interval vs. coitally dependent PRE-EXPOSURE PROPHYLAXIS (PrEP) intermittent oral TDF/FTC in women and Completion of CDC 4370, phase II/III PARTNER TREATMENT MSM (Thailand and select African (Thailand) MICROBICIDE countries) Results expected first quarter 2011. * Trial start- and end-dates are estimates—dates may change. Additional efficacy trials and details are available on the timeline inside. Trials listed on the timeline are subject to interim analyses during the year. A Quarterly Update Px Wire: on HIV Prevention Research Volume 3 | No. 1 January–March 2010 Australia ONGOING TRIALS OF NEW PREVENTION OPTIONS WORLDWIDE Belgium Botswana Brazil Canada Sweden China Canada Russia United Kingdom Dominican Republic Belgium Germany Ecuador France Switzerland France United States China Germany Dominican Republic Haiti Haiti Jamaica Puerto Rico India India Thailand Jamaica Kenya Uganda Malawi Ecuador Kenya Rwanda Peru Tanzania Peru Brazil Puerto Rico Zambia Malawi Russia Zimbabwe Botswana Australia Rwanda South Africa South Africa Sweden Switzerland Tanzania Thailand Uganda United Kingdom United States Zambia Zimbabwe VACCINES MICROBICIDES PRE-EXPOSURE PROPHYLAXIS (PrEP) PrEP & MICROBICIDE PARTNER TREATMENT BIOMEDICAL HIV PREVENTION RESEARCH: A COMPREHENSIVE TIMELINE OF EFFICACY TRIAL RESULTS* 2007 2008 2009 2010 2011 2012+ CONRAD CELLULOSE SULFATE HSV-2 SUPPRESSION (HPTN 039) HPTN 035 CDC 4323 iPrEx PARTNERS PrEP Phase III trial to evaluate the effect Phase III trial to evaluate suppressive Phase II/IIb trial to evaluate the Phase II trial to evaluate the clinical Phase III trial to evaluate the safety Phase III trial to evaluate the safety of cellulose sulfate gel on vaginal HIV acyclovir treatment for the reduction safety and effectiveness of the and behavioral safety of once-daily and efficacy of once-daily oral and efficacy of two different strate- transmission in women (Benin, India, of HIV infection in HSV-2 seropositive vaginal microbicides, BufferGel and oral TDF among men who have sex TDF/FTC to prevent HIV infection gies to prevent HIV transmission in South Africa, Uganda, Zimbabwe) women and men who have sex with 0.5% PRO 2000/5 gel, to prevent HIV with men (US) among men who have sex with men HIV-serodiscordant couples: once- Trial stopped early. No evidence of men (Peru, South Africa, US, Zambia, infection in women (Malawi, South Release of results expected February (Brazil, Ecuador, Peru, South Africa, daily oral TDF and once-daily oral benefit. There were more infections Zimbabwe) Africa, US, Zambia, Zimbabwe) 2010. Thailand, US) TDF/FTC (Kenya, Uganda) among women using the gel than No evidence of benefit. There were fewer infections in women those using placebo, but this was not using PRO 2000 than women using CAPRISA 004 FEM-PrEP statistically significant. MALE CIRCUMCISION IN HIV- the placebo gel, but this difference Phase IIb trial to evaluate the safety Phase III trial to evaluate the safety POSITIVE MEN was not statistically significant. No and effectiveness of 1% tenofovir gel and effectiveness of once-daily FHI CELLULOSE SULFATE Large-scale trial to evaluate the evidence of benefit in women using to prevent HIV infection in women oral TDF/FTC for HIV prevention in Phase III trial to evaluate the safety safety of male circumcision and BufferGel. (South Africa) women (Kenya, Malawi, South Africa, and effectiveness of cellulose sulfate its potential protective effect for Release of results expected July 2010. Tanzania, Zambia) gel to prevent HIV infection in women HIV-negative female partners of HIV- PARTNERS IN PREVENTION (Nigeria) positive circumcised males (Uganda) Phase III study to evaluate the effect CDC 4370 HVTN 505 Trial stopped following announce- Trial stopped enrollment, December of suppressive acyclovir treatment Phase II/III trial to evaluate the safety Phase II test-of-concept trial to ment of data from CONRAD trial. No 2006. No statistically significant con- for HSV-2 on HIV transmission in and efficacy of once-daily oral TDF evaluate the safety and effect on evidence of safety concerns or of clusions could be drawn from sample HIV-serodiscordant couples to prevent HIV infection in injecting post-HIV infection viral load of the effectiveness. size. However, men who resumed sex (Botswana, Kenya, Rwanda, South drug users (Thailand) VRC’s DNA prime / Ad5-boost vaccine prior to wound healing were more Africa, Tanzania, Uganda, Zambia) strategy in HIV-negative, Ad5-sero- MIRA likely to transmit HIV to their female No evidence of reduced rates of HIV CDC 4940 (TDF2) negative and circumcised men who Phase III trial to evaluate effective- partners. transmission, but there were reduced Phase II trial to evaluate the safety of have sex with men (US) ness of the female diaphragm to rates of genital ulcers and HIV once-daily oral TDF/FTC in prevent HIV infection (South Africa, CARRAGUARD viral load. heterosexual men and women VOICE (MTN-003) Zimbabwe) Phase III trial to evaluate the safety (Botswana) Phase IIb trial to evaluate the safety No evidence of benefit. and efficacy of the vaginal micro- ALVAC-AIDSVAX (RV 144) and effectiveness of three different bicide Carraguard to prevent HIV Phase III trial to evaluate the safety strategies to prevent HIV in women: STEP (HVTN 502/Merck 023) infection in women (South Africa) and efficacy of a prime-boost vac- once-daily oral TDF, once-daily oral Phase IIb test-of-concept trial to No evidence of benefit. cine strategy (ALVAC plus AIDSVAX) TDF/FTC, and 1% tenofovir gel (South evaluate safety and efficacy of to prevent HIV infection (Thailand) Africa, Uganda, Zambia, Zimbabwe) Merck’s Ad5 candidate (Australia, Initial data show that vaccine Brazil, Canada, Dom. Rep., Haiti, recipients were 31% less likely than HPTN 052 Jamaica, Peru, Puerto Rico, US) placebo recipients to become HIV- Phase III trial to evaluate the ef- Trial halted immunizations, September infected.